Baxter International Inc. (BAX) News
Track canonical SquawkNews coverage tagged to BAX, Baxter International Inc.. This hub brings together deduplicated headlines about united states, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 22 indexed stories across 10 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
BAX: Operational progress, innovation, and debt reduction set the stage for future growth and value
Decentralization, continuous improvement, and debt reduction are driving operational and financial progress, with new leadership and product innovation supporting future growth. Business segments show mixed performance,
EQUITY | Sep 09, 2026, 06:32 PM UTC
L
BAX: Operational progress, margin expansion, and innovation drive growth amid ongoing portfolio optimization
Decentralization, continuous improvement, and debt reduction are driving operational and financial progress, with new leadership and product innovation supporting growth. Margin expansion and portfolio optimization remai
EQUITY | Sep 09, 2026, 05:55 PM UTC
H
Shares of medical device-related companies are trading lower amid possible sympathy with Boston Scientific after that company announced it w
Shares of medical device-related companies are trading lower amid possible sympathy with Boston Scientific after that company announced it was likely to miss its FY26 and Q3 adjusted EPS and net sales growth guidance fol
EARNINGS | Sep 08, 2026, 04:05 PM UTC
L
Sector underperformers include ADM, AEP, APA, BAX, BG
Hammerstone MarketTalk lists ADM, AEP, APA, BAX and BG among underperformers versus their S&P sector ETFs, with no catalyst supplied.
EQUITY | Aug 21, 2026, 07:47 PM UTC
L
Baxter appoints John Rogers as chief financial officer
Baxter appoints John Rogers as its chief financial officer, according to the company announcement.
EQUITY | Aug 19, 2026, 12:05 PM UTC
H
Baxter (BAX) prices upsized cash tender offers
Baxter announces the pricing for its upsized cash tender offers, but the feed provides no offer size, settlement terms, or exact pricing details.
MNA | Aug 18, 2026, 09:06 PM UTC
H
Baxter shares early tender results; upsizes prior cash tender offers
Baxter (BAX) reports early tender results and upsizes previously announced cash tender offers, as part of its ongoing tender offer activity.
MNA | Aug 18, 2026, 01:01 PM UTC
H
Banks Upgrade AXTI, IP, PLXS, SAIA
Banks upgrade multiple stocks
EQUITY | Jul 31, 2026, 11:38 AM UTC
H
BAX Upgraded to Neutral
BAX upgraded to Neutral from Sell
EQUITY | Jul 31, 2026, 10:41 AM UTC
H
Baxter Jumps After Q2 Beat, Boosted 2026 Guidance Reflects Turnaround Progress
Baxter International Inc. (NYSE: BAX ) stock is trading higher on Thursday after the company reported better-than-expected second-quarter financial results and raised its fiscal 2026 guidance. • Baxter International shar
EARNINGS | Jul 30, 2026, 03:34 PM UTC
H
BAX +16% after Q2 net sales above expectations ($2.96B vs $2.8B est) and management raising FY organic sales growth guide to +2-3% vs flat p
BAX +16% after Q2 net sales above expectations ($2.96B vs $2.8B est) and management raising FY organic sales growth guide to +2-3% vs flat previously. FY EPS guide $1.95-2.15 ex-items vs prior guidance $1.85-2.05. Revenu
EARNINGS | Jul 30, 2026, 01:54 PM UTC
H
BAX raises annual profit forecast
BAX raises annual profit forecast
EARNINGS | Jul 30, 2026, 01:38 PM UTC
H
Baxter rises 13% on Q2 revenue
Baxter Q2 revenue climbs
EQUITY | Jul 30, 2026, 11:42 AM UTC
L
BAX - Baxter Reports Second-Quarter 2026 Results
BAX - Baxter Reports Second-Quarter 2026 Results
EQUITY | Jul 30, 2026, 11:17 AM UTC
H
Baxter raises sales growth outlook
Baxter raises full-year sales growth outlook
EARNINGS | Jul 30, 2026, 11:16 AM UTC
H
Baxter International Raises FY2026 Adj EPS Guidance from $1.85-$2.05 to $1.95-$2.15 vs $1.91 Est; Raises FY2026 Sales Guidance from $11.244B
Baxter International (NYSE: BAX ) raises FY2026 Adj EPS guidance from $1.85-$2.05 to $1.95-$2.15 vs $1.91 analyst estimate. Raises FY2026 sales outlook from $11.244 billion-$11.356 billion to $11.581 billion-$11.694 bill
EARNINGS | Jul 30, 2026, 11:16 AM UTC
H
BAX Baxter RESULTS: Q2, Q2 ADJ EPS $0.54 vs. EST $0.37, Q2 REV $2.960B vs. EST $2.795B, Q2 Net Income $126M, Baxter Earnings Notes:, Outlook
BAX Baxter RESULTS: Q2, Q2 ADJ EPS $0.54 vs. EST $0.37, Q2 REV $2.960B vs. EST $2.795B, Q2 Net Income $126M, Baxter Earnings Notes:, Outlook FY REV growth 3-4%, Outlook FY ADJ EPS $1.95-2.15 vs. EST $1.91
EARNINGS | Jul 30, 2026, 11:15 AM UTC
L
BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS
BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS
EQUITY | Jul 28, 2026, 11:47 AM UTC
L
BAX Baxter: changes do not impact Co's previously issued Consolidated financial statements except for its segment disclosures
BAX Baxter: changes do not impact Co's previously issued Consolidated financial statements except for its segment disclosures
EQUITY | Jul 14, 2026, 08:20 PM UTC
L
BAX Baxter - shared corporate expenses to remain unallocated in segment reporting - SEC filing
BAX Baxter - shared corporate expenses to remain unallocated in segment reporting - SEC filing
REGULATION | Jul 14, 2026, 08:18 PM UTC
L
BAX Baxter - changes reportable segments to two segments effective Q2 2026 - SEC filing - Pharmaceuticals segment now reported within infusi
BAX Baxter - changes reportable segments to two segments effective Q2 2026 - SEC filing - Pharmaceuticals segment now reported within infusion Therapies & platforms division - SEC filing
REGULATION | Jul 14, 2026, 08:17 PM UTC
L
Evercore ISI Adjusts Price Target on Baxter International to $24 From $22
() -- Baxter International (BAX) has an average rating of hold and mean price target of $19.90, according to analysts polled by FactSet. ( covers equity, commodity and economic research from major banks and research firm
EQUITY | Jul 06, 2026, 01:22 PM UTC